Abstract | BACKGROUND: OBJECTIVE: To review discovery and development of synthetic CpG ODNs and their effects on immune cells and to relate preclinical and early clinical development of PF-3512676. METHODS: A literature search was performed on databases available through the National Library of Medicine (PubMed), the European Society of Medical Oncology and the American Society of Clinical Oncology. RESULTS/CONCLUSIONS: Unmethylated CpG motifs were identified as the element of bacillus Calmette-Guérin responsible for immunostimulatory activity. Preclinical studies identified the mechanism of action (i.e., TLR9) and an optimal human sequence for antitumor activity. On the basis of preclinical studies, PF-3512676, a B-class CpG ODN, was selected for further clinical development. Phase I/II clinical trials have shown PF-3512676 to be well tolerated and to have antitumor activity as a single agent in patients with several types of advanced cancer, and to show promise as a vaccine adjuvant.
|
Authors | Ahmad A Tarhini, John M Kirkwood, Arthur M Krieg |
Journal | Expert opinion on drug discovery
(Expert Opin Drug Discov)
Vol. 4
Issue 5
Pg. 587-603
(May 2009)
ISSN: 1746-0441 [Print] England |
PMID | 23485088
(Publication Type: Journal Article)
|